BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET APPLICATION

早期非类固醇避孕药的发现和发展受到已知靶点的限制 并且容易地访问该信息。重要的是要促进发现、管理 和避孕目标的可用性，目的是开发新的方法来促进 下一代安全避孕药/装置。为了缓解这一障碍，生物信息学推动了 建立了从现有数据库中确定和管理这些目标的办法。至 进一步允许该数据库的易访问性和友好的用户界面，Web应用程序是 需要的。生物检测设施拥有生物信息学和网页设计与应用 实现这一任务的能力，除了允许快速评估(体外和体内)新的 物质与目标的组成、疗效评价、安全性/毒理学评价、药物 临床批次后的避孕药制剂、给药系统和装置 将在临床试验中评估的药物的制备/释放和持续稳定性测试。这个 BTF提供全面的项目管理和支持新目标所有阶段的能力 产品识别、药物发现/优化、临床前活动和开发 避孕药具和相关任务导致提交研究用新药(IND) 申请。

Early phase non-steroidal contraceptive discovery and development is limited by known targets and readily accessibility of this information. It is important to facilitate the discovery, curation and availability of contraceptive targets with the aim of developing new approaches to advance next generation of safe contraceptive drug/device. To alleviate this obstacle, bioinformatics driven approach to identify and curate those targets from the existing databases was established. To further allow easy accessibility and friendly user interface for this database, a web application is needed. The Biological Testing Facility has bioinformatics and web design and application capability to achieve this task, in addition to permit rapid evaluation (in vitro and in vivo) of new compositions of matter to the target, efficacy evaluation, safety/ toxicology assessment, drug formulations, delivery systems, and devices for contraceptives followed by clinical batch preparation/ release and continued stability testing of drugs to be evaluated in clinical trials. The BTF provides overall project management and the capabilities to support all phases of novel target product identification, drug discovery/ optimization, preclinical activities and development of contraceptives and associated tasks leading to the filing of investigational new drug (IND) applications.